NCT03618550 2025-12-02Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer CenterPhase 2 Recruiting257 enrolled
NCT02733380 2020-04-01Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaHenan Cancer HospitalPhase 2 Unknown20 enrolled